ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$6.52
-0.28 (-4.12%)
▼
5d:
-17.15%
30d:
+28.09%
90d:
+84.18%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Smart Money Accumulation
None View Scanner →
Strength: 6.8/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ABCL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABCL is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABCL is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $6.52, which is considered fair relative to its 30-day fair value range of $5.33 to $7.44.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $6.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+61.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $6.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+61.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.33 -
$7.44
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 61.0% below Wall St target ($10.50)
- WARNING: Recommendation downgraded due to -17.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.33 -
$7.44
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.40
Resistance Level
$8.44
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.06
Wall Street Target
$10.50
(+61.0%)
Revenue Growth (YoY)
96.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-181.7%
Share & Embed Analysis
Last updated: July 13, 2026 8:21 PM ET
Data refreshes hourly during market hours. Next update: 9:21 PM
Data refreshes hourly during market hours. Next update: 9:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
